Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection
AL Beitelshees et al, Genetics in Medicine, July 17, 2020
AL Beitelshees et al, Genetics in Medicine, July 17, 2020
We assembled a cohort of patients from eight sites performing CYP2C19 genotyping to inform antiplatelet therapy. More than half of patients genotyped received another medication impacted by CYP2C19 in the following year. Given that genotype is stable for a patient’s lifetime, this finding has implications beyond the indication for which it was originally performed.
.png)
No hay comentarios:
Publicar un comentario